Merus
Manufacturing · Netherlands · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Uppsalalaan 17, Utrecht, Utrecht, 3584, ...Phone Number
+31 850162500Website
www.merus.nlRevenue
$87.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Merus
Merus, is a clinical-stage oncology company developing innovative full-length bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Merus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Merus launches new products
Click to see if Merus had a recent Job posting/layoffs
Check if Merus has recently received funding, and reach out quickly before it becomes old news!
Check out if Merus is spiking on competitors!
Website visits: Recent activity has been detected on your website
Merus, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Merus recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Merus
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Merus has new funding data
Recommended Actions
Find VP level buyers at Merus
Find 3 more new buyers
Company Profile Activity
Activity Insights
Merus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Merus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Merus.
Merus financials insights
Gather financial insights about Merus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Stock Offering
$60M
Merus Tech Stack
A closer look at the technologies used by Merus
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Person-Based
Person-Based
Person-Based
Merus News & Media
How Genmab's US$2.5 Billion Merus Deal Financing Could Impact Genmab (CPSE:GMAB) Investors
In early December 2025, Genmab A/S completed a US$1.50 billion offering of 6.250% senior secured notes due 2032 and US$1.00 billion of 7.250% senior unsecured notes due 2033, alongside new credit facilities, to help fund its planned acquisition of Merus N.V. and related costs. The complex financing structure, including secured and unsecured notes held initially in segregated accounts and governed by covenants limiting additional leverage and payouts, highlights how Genmab is reshaping its...Merus N.V. (MRUS): A Bull Case Theory
We came across a bullish thesis on Merus N.V. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on MRUS. Merus N.V.’s share was trading at $95.99 as of December 2nd. Genmab’s acquisition of Merus for $97 per share has been well received by the market, with Genmab’s stock reacting positively despite the […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Merus
Sign Up For FreeTo access detailed company insights
Merus, is a clinical-stage oncology company developing innovative full-length bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclona... Read More
